title: Pancreatitis associated with incretin-based therapies.
authors.forename: Shridhar N
authors.initials: SN
authors.lastname: Iyer
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Tanenberg
authors.forename: Carlos E
authors.initials: CE
authors.lastname: Mendez
authors.forename: R Lee
authors.initials: RL
authors.lastname: West
authors.forename: Almond J
authors.initials: AJ
authors.lastname: Drake
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D054795:Incretins; D010195:Pancreatitis / Q000139:chemically induced* / Q000175:diagnosis*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use; D014688:Venoms / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins; D010455:Peptides; D011719:Pyrazines; D014230:Triazoles; D014688:Venoms; D000077270:Exenatide; D000068900:Sitagliptin Phosphate